Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Cabometyx, cabozantinib, Date of authorisation: 09/09/2016, Revision: 21, Status: Authorised

Agenda of the HMPC meeting 2-4 March 2026

List of centrally authorised products with safety-related changes to the product information

Human medicines European public assessment report (EPAR): Fubelv, etanercept, Status: Opinion

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Status: Opinion

Human medicines European public assessment report (EPAR): Dazparda, insulin aspart, Status: Opinion

Human medicines European public assessment report (EPAR): mCOMBRIAX, Influenza,COVID-19 mRNA vaccine, Status: Opinion

Human medicines European public assessment report (EPAR): Ojemda, tovorafenib, Status: Opinion

Human medicines European public assessment report (EPAR): Onerji, levodopa,carbidopa, Status: Opinion